Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | LIPC | P11150 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25204156 | 0.97 | GPR119 (0.44) | GPR119KDM1ACHRM1TLR8PTPN2 | |
| SCHEMBL25234471 | 0.92 | GPR119 (0.41) | GPR119TLR8PTPN2PTPN1PTPN6 | |
| SCHEMBL25217227 | 0.91 | GPR119 (0.42) | GPR119KDM1APTPN2PTPN1PTPN6 | |
| SCHEMBL25199411 | 0.88 | FGFR1 (0.39) | GPR119TLR8 | |
| SCHEMBL25224232 | 0.88 | TLR8 (0.45) | GPR119TLR8 | |
| SCHEMBL25204298 | 0.86 | GPR119 (0.42) | GPR119PTPN2PTPN1PTPN6TTK | |
| SCHEMBL30461850 | 0.86 | GPR119 (0.42) | GPR119PTPN2PTPN1PTPN6TTK | |
| SCHEMBL25217654 | 0.85 | LIPC (0.45) | GPR119PTPN2PTPN1PTPN6TTK | |
| SCHEMBL25209249 | 0.85 | GPR119 (0.41) | GPR119PTPN2PTPN1PTPN6TTK | |
| SCHEMBL30461813 | 0.85 | LIPC (0.45) | GPR119PTPN2PTPN1PTPN6TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4436961-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023097007-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | GPR119 4012/4885KDM1A 4467/4885CHRM1 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.